The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice

International Journal of Stroke

Volumn 7, Issue 4, 2012, Pages 289-292

  Dirks, Maaike ^a   Niessen, Louis W ^b,c,d   van Wijngaarden, Jeroen ^d   Koudstaal, Peter J ^a   Franke, Cees L ^e   van Oostenbrugge, Robert J ^f   Dippel, Diederik W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e Zuyderland Medical Centre   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Daily practice; Safety; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OBSERVATIONAL STUDY; PATIENT SAFETY; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84861117888     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00709.x     Document Type: Article

References (11)

1. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
3. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; 4:CD000213.
4. Maasland L, van Oostenbrugge RJ, Franke CF etal. Patients enrolled in large randomized clinical trials of antiplatelet treatment for prevention after transient ischemic attack or ischemic stroke are not representative of patients in clinical practice: the Netherlands Stroke Survey. Stroke 2009; 40:2662-2668.
5. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?'. Lancet 2005; 365:82-93.
6. Reeves MJ, Arora S, Broderick JP etal. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005; 36:1232-1240.
7. Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D. Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry 2010; 82:14-19.
8. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-282.
9. Dirks M, Niessen LW, Huijsman R etal. Promoting acute thrombolysis for ischaemic stroke (PRACTISE). Protocol for a cluster randomised controlled trial to assess the effect of implementation strategies on the rate and effects of thrombolysis for acute ischaemic stroke (ISRCTN 20405426). Int J Stroke 2007; 2:151-159.
10. Hacke W, Kaste M, Fieschi C etal. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
11. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245-1251.